Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6287)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 26, 2021 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: PMC8316870 DOI: 10.4252/wjsc.v13.i7.795] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i7/795.htm |
| Number | Citing Articles |
| 1 |
Uasim Harkus, Miriam Wankell, Pranavan Palamuthusingam, Craig McFarlane, Lionel Hebbard. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data. Seminars in Cancer Biology 2022; 86: 799 doi: 10.1016/j.semcancer.2022.01.005
|
| 2 |
Jonathan Charles, Andrea Vrionis, Arian Mansur, Trevor Mathias, Jamil Shaikh, Aaron Ciner, Yixing Jiang, Nariman Nezami. Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies. Cancers 2023; 15(9): 2624 doi: 10.3390/cancers15092624
|
| 3 |
Xue-Qin Gong, Ning Liu, Yun-Yun Tao, Li Li, Zu-Mao Li, Lin Yang, Xiao-Ming Zhang. Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-34763-y
|
| 4 |
Akanksha Suresh, Renumathy Dhanasekaran. Hepatobiliary Cancers: Translational Advances and Molecular Medicine. Advances in Cancer Research 2022; 156: 103 doi: 10.1016/bs.acr.2022.01.007
|
| 5 |
Ling-Wu Tong, Yong-Shan Hu, Shi-Jing Yu, Cheng-Lei Li, Jing-Wei Shao. Current application and future perspective of CRISPR/cas9 gene editing system mediated immune checkpoint for liver cancer treatment. Nanotechnology 2024; 35(40): 402002 doi: 10.1088/1361-6528/ad5f33
|
| 6 |
Caecilia Sukowati, Loraine Kay D. Cabral, Claudio Tiribelli. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle. Annals of Hepatology 2022; 27(5): 100740 doi: 10.1016/j.aohep.2022.100740
|
| 7 |
Lorenza Di Marco, Adriana Romanzi, Alessandra Pivetti, Nicola De Maria, Federico Ravaioli, Massimiliano Salati, Erica Villa, Fabrizio Di Benedetto, Paolo Magistri, Massimo Dominici, Antonio Colecchia, Stefano Di Sandro, Andrea Spallanzani. Suppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation. Critical Reviews in Oncology/Hematology 2025; 207: 104607 doi: 10.1016/j.critrevonc.2024.104607
|
| 8 |
Caecilia Sukowati, Loraine Kay D. Cabral, Beatrice Anfuso, Francesco Dituri, Roberto Negro, Gianluigi Giannelli, Claudio Tiribelli. PD-L1 Downregulation and DNA Methylation Inhibition for Molecular Therapy against Cancer Stem Cells in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2023; 24(17): 13357 doi: 10.3390/ijms241713357
|